Dec 31, 2022

Revolution Medicines Q4 2022 Earnings Report

Total Revenue
$15.3M
Previous year: $9.46M
+62.1%
EPS
-$0.63
Previous year: -$0.71
-11.3%
R&D Expenses
$66.1M
G&A Expenses
$10.9M
Cash Balance
$645M
Gross Profit
$12.7M
Previous year: $7.4M
+72.1%
Cash and Equivalents
$161M
Previous year: $108M
+48.8%
Free Cash Flow
-$64.7M
Previous year: -$40.4M
+59.9%
Total Assets
$812M
Previous year: $738M
+10.0%

Revolution Medicines

Revolution Medicines